Table 3.

Univariate Analysis for Progression-Free Survival in Patients with KRAS Mutation and Advanced NSCLC

Variables	PFSa			PFSb			PFSc
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
KRAS G12C (with vs. without)	0.357	0.15–0.85	0.02	0.65	0.11–3.83	0.63	0.46	0.2–1.05	0.06
Gender (female vs. male)	1.63	0.73–3.69	0.23	2.09	0.38–11.52	0.4	1.04	0.44–2.47	0.92
Age (≥60 vs.<60 years)	0.6	0.28–1.27	0.18	0.4	0.07–2.26	0.3	0.52	0.25–1.1	0.09
Smoke, (never vs. current/former)	1.202	0.45–3.17	0.71	–	–	–	2.06	0.71–5.95	0.18
Histology (adenocarcinoma vs. nonadenocarcinoma)	1.61	0.37–6.92	0.52	1.85	0.21–16.38	0.56	1.86	0.43–8.12	0.41
ECOG PS (3–4 vs. 0–2)	1.44	0.58–3.54	0.43	2.11	0.38–11.62	0.39	1.72	0.7–4.23	0.24
PD-L1 expression (yes vs. no)	0.47	0.1–2.11	0.32	–	–	–	0.24	0.04–1.41	1.11
Brain metastasis (yes vs. no)	1.26	0.54–2.93	0.59	–	–	–	1.0	0.43–2.35	1.00
Bone metastasis (yes vs. no)	1.58	0.76–3.31	0.22	1.16	0.23–5.78	0.85	1.49	0.72–3.1	0.29
d1st-line chemo	0.59	0.33–1.04	0.07	0.65	0.28–1.52	0.32	1.07	0.73–1.58	0.72
e2nd-line chemo	28.86	3.92–212.4	–	–	–	-	23.92	3.25–176.14	–

^a1st-line chemotherapy.

^b2nd-line chemotherapy.

^cData on 1st-line and 2nd-line chemotherapy and the multivariate analysis were not available. PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, Programmed death-ligand 1.

^d1st-line chemo: pemetrexed-based vs. taxanes-based vs. gemcitabine-based vs. no-chemo, no-chemo as reference.

^e2nd-line chemo: chemo vs. no-chemo, no-chemo as reference.